Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Recently, it was argued that clinically important differences should play no role in sample size calculations. Instead, it was proposed that sample size calculations should focus on setting realistic estimates of treatment benefit. We disagree, and argue in this article that considering the importance of a target difference is necessary in the context of randomised controlled trials of effectiveness, particularly definitive phase III trials. Ignoring clinical importance could have serious ethical and practical consequences.

Original publication

DOI

10.1186/s13063-023-07532-5

Type

Journal article

Journal

Trials

Publication Date

04/08/2023

Volume

24

Keywords

Assumed benefit, Clinical trial, Clinically relevant difference, Effect size, Minimum important difference, Power, RCT, Target difference, Humans, Clinical Relevance, Sample Size, Randomized Controlled Trials as Topic